Bellevue Asset Management AG historic quarter change: USA Stocks, Added
In share positions in stocks (listed in the US), over 3 quarters from 2015-03-31 to 2015-12-31, Bellevue Asset Management AG opened 12 positions, added to 67, reduced 48 and sold out of 7.
- Q4 2015: Stock CAH; Country of operation United States; Class COM; Shares before 80,000.
- Q4 2015: Stock CNC; Country of operation United States; Class COM; Shares before 20,000.
- Q4 2015: Stock BIIB; Country of operation United States; Class COM; Shares before 71,770.
- Q4 2015: Stock CVS; Country of operation United States; Class COM; Shares before 55,000.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1642343), 3 quarters: Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-12); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-12); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-12). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2015-03-31.
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2015 | CAH Cardinal Health, Inc. | United States | COM | 80,000 | 171,480 | +91,480 | $6,146,000 | $15,308,000 | +$9,162,000 | 2016-02-12 |
| Q4 2015 | CNC Centene Corporation | United States | COM | 20,000 | 105,630 | +85,630 | $1,085,000 | $6,952,000 | +$5,867,000 | 2016-02-12 |
| Q4 2015 | BIIB Biogen Inc. | United States | COM | 71,770 | 84,030 | +12,260 | $20,943,000 | $25,743,000 | +$4,800,000 | 2016-02-12 |
| Q4 2015 | CVS CVS Health Corporation | United States | COM | 55,000 | 96,200 | +41,200 | $5,306,000 | $9,405,000 | +$4,099,000 | 2016-02-12 |
| Q4 2015 | BDX Becton, Dickinson and Company | United States | COM | 92,305 | 105,075 | +12,770 | $12,245,000 | $16,191,000 | +$3,946,000 | 2016-02-12 |
| Q4 2015 | AMGN Amgen Inc. | United States | COM | 120,000 | 123,000 | +3,000 | $16,598,000 | $19,967,000 | +$3,369,000 | 2016-02-12 |
| Q4 2015 | BAX Baxter International Inc. | United States | COM | 50,000 | 110,000 | +60,000 | $1,643,000 | $4,197,000 | +$2,554,000 | 2016-02-12 |
| Q4 2015 | CYH Community Health Systems, Inc. | United States | COM | 162,340 | 174,440 | +12,100 | $6,943,000 | $4,628,000 | -$2,315,000 | 2016-02-12 |
| Q4 2015 | HALO Halozyme Therapeutics, Inc. | United States | COM | 246,000 | 318,000 | +72,000 | $3,304,000 | $5,511,000 | +$2,207,000 | 2016-02-12 |
| Q4 2015 | ILMN Illumina, Inc. | United States | COM | 87,625 | 91,425 | +3,800 | $15,406,000 | $17,549,000 | +$2,143,000 | 2016-02-12 |
| Q4 2015 | BSX Boston Scientific Corporation | United States | COM | 400,000 | 460,000 | +60,000 | $6,564,000 | $8,482,000 | +$1,918,000 | 2016-02-12 |
| Q4 2015 | ALKS Alkermes Public Limited Company | SHS | 59,000 | 65,500 | +6,500 | $3,462,000 | $5,199,000 | +$1,737,000 | 2016-02-12 | |
| Q4 2015 | PRTA Prothena Corporation plc | Ireland | SHS | 15,000 | 31,000 | +16,000 | $680,000 | $2,111,000 | +$1,431,000 | 2016-02-12 |
| Q4 2015 | CHRS Coherus BioSciences, Inc | United States | COM | 230,000 | 257,000 | +27,000 | $4,609,000 | $5,901,000 | +$1,292,000 | 2016-02-12 |
| Q4 2015 | JAZZ Jazz Pharmaceuticals Public Limited Company | SHS USD | 56,000 | 60,000 | +4,000 | $7,437,000 | $8,434,000 | +$997,000 | 2016-02-12 | |
| Q4 2015 | HCA HCA Holdings, Inc. | United States | COM | 40,000 | 60,000 | +20,000 | $3,094,000 | $4,058,000 | +$964,000 | 2016-02-12 |
| Q4 2015 | COR AmerisourceBergen Corporation | United States | COM | 60,000 | 64,000 | +4,000 | $5,699,000 | $6,637,000 | +$938,000 | 2016-02-12 |
| Q4 2015 | MCK McKesson Corporation | United States | COM | 41,000 | 43,000 | +2,000 | $7,586,000 | $8,481,000 | +$895,000 | 2016-02-12 |
| Q4 2015 | PFE Pfizer Inc. | United States | COM | 85,000 | 110,000 | +25,000 | $2,670,000 | $3,551,000 | +$881,000 | 2016-02-12 |
| Q4 2015 | EW Edwards Lifesciences Corporation | United States | COM | 44,500 | 69,000 | +24,500 | $6,327,000 | $5,450,000 | -$877,000 | 2016-02-12 |
| Q4 2015 | SUPN Supernus Pharmaceuticals, Inc. | United States | COM | 320,000 | 355,000 | +35,000 | $4,490,000 | $4,771,000 | +$281,000 | 2016-02-12 |
| Q4 2015 | INFIQ Infinity Pharmaceuticals, Inc. | United States | COM | 130,000 | 160,000 | +30,000 | $1,099,000 | $1,256,000 | +$157,000 | 2016-02-12 |
| Q4 2015 | EXEL Exelixis, Inc. | United States | COM | 150,000 | 170,000 | +20,000 | $842,000 | $959,000 | +$117,000 | 2016-02-12 |
| Q4 2015 | PRGO Perrigo Company plc | Ireland | SHS | 40,000 | 44,000 | +4,000 | $6,291,000 | $6,367,000 | +$76,000 | 2016-02-12 |
| Q4 2015 | INCY Incyte Corporation | United States | COM | 77,000 | 79,000 | +2,000 | $8,495,000 | $8,568,000 | +$73,000 | 2016-02-12 |
| Q3 2015 | ILMN Illumina, Inc. | United States | COM | 82,739 | 87,625 | +4,886 | $18,067,000 | $15,406,000 | -$2,661,000 | 2015-11-12 |
| Q3 2015 | GILD Gilead Sciences, Inc. | United States | COM | 234,900 | 254,050 | +19,150 | $27,502,000 | $24,945,000 | -$2,557,000 | 2015-11-12 |
| Q3 2015 | INCY Incyte Corporation | United States | COM | 57,000 | 77,000 | +20,000 | $5,940,000 | $8,495,000 | +$2,555,000 | 2015-11-12 |
| Q3 2015 | CYH Community Health Systems, Inc. | United States | COM | 148,250 | 162,340 | +14,090 | $9,335,000 | $6,943,000 | -$2,392,000 | 2015-11-12 |
| Q3 2015 | THC Tenet Healthcare Corporation | United States | COM NEW | 121,950 | 126,510 | +4,560 | $7,058,000 | $4,671,000 | -$2,387,000 | 2015-11-12 |
| Q3 2015 | AMGN Amgen Inc. | United States | COM | 96,866 | 120,000 | +23,134 | $14,871,000 | $16,598,000 | +$1,727,000 | 2015-11-12 |
| Q3 2015 | REGN Regeneron Pharmaceuticals, Inc. | United States | COM | 38,800 | 38,900 | +100 | $19,793,000 | $18,094,000 | -$1,699,000 | 2015-11-12 |
| Q3 2015 | EW Edwards Lifesciences Corporation | United States | COM | 34,100 | 44,500 | +10,400 | $4,857,000 | $6,327,000 | +$1,470,000 | 2015-11-12 |
| Q3 2015 | MGNX Macrogenics, Inc. | United States | COM | 81,000 | 83,000 | +2,000 | $3,076,000 | $1,778,000 | -$1,298,000 | 2015-11-12 |
| Q3 2015 | ESPR Esperion Therapeutics Inc. | United States | COM | 27,000 | 40,000 | +13,000 | $2,208,000 | $944,000 | -$1,264,000 | 2015-11-12 |
| Q3 2015 | LLY Lilly Eli & Co. | United States | COM | 20,000 | 35,000 | +15,000 | $1,670,000 | $2,929,000 | +$1,259,000 | 2015-11-12 |
| Q3 2015 | HALO Halozyme Therapeutics, Inc. | United States | COM | 91,616 | 246,000 | +154,384 | $2,069,000 | $3,304,000 | +$1,235,000 | 2015-11-12 |
| Q3 2015 | HUM Humana, Inc. | United States | COM | 23,500 | 30,000 | +6,500 | $4,495,000 | $5,370,000 | +$875,000 | 2015-11-12 |
| Q3 2015 | TMO Thermo Fisher Scientific Inc. | United States | COM | 13,000 | 20,000 | +7,000 | $1,687,000 | $2,446,000 | +$759,000 | 2015-11-12 |
| Q3 2015 | AGIO Agios Pharmaceuticals, Inc. | United States | COM | 41,000 | 54,000 | +13,000 | $4,557,000 | $3,812,000 | -$745,000 | 2015-11-12 |
| Q3 2015 | BDX Becton, Dickinson and Company | United States | COM | 90,630 | 92,305 | +1,675 | $12,838,000 | $12,245,000 | -$593,000 | 2015-11-12 |
| Q3 2015 | LGND Ligand Pharmaceuticals Incorporated | United States | COM NEW | 76,190 | 95,730 | +19,540 | $7,688,000 | $8,199,000 | +$511,000 | 2015-11-12 |
| Q3 2015 | EXEL Exelixis, Inc. | United States | COM | 100,000 | 150,000 | +50,000 | $376,000 | $842,000 | +$466,000 | 2015-11-12 |
| Q3 2015 | CNC Centene Corporation | United States | COM | 15,000 | 20,000 | +5,000 | $1,206,000 | $1,085,000 | -$121,000 | 2015-11-12 |
| Q3 2015 | UNH UnitedHealth Group Incorporated | United States | COM | 115,000 | 120,000 | +5,000 | $14,030,000 | $13,921,000 | -$109,000 | 2015-11-12 |
| Q3 2015 | CVS CVS Health Corporation | United States | COM | 50,000 | 55,000 | +5,000 | $5,244,000 | $5,306,000 | +$62,000 | 2015-11-12 |
| Q3 2015 | PRTA Prothena Corporation plc | Ireland | SHS | 13,000 | 15,000 | +2,000 | $685,000 | $680,000 | -$5,000 | 2015-11-12 |
| Q2 2015 | ILMN Illumina, Inc. | United States | COM | 55,559 | 82,739 | +27,180 | $10,314,000 | $18,067,000 | +$7,753,000 | 2015-08-12 |
| Q2 2015 | REGN Regeneron Pharmaceuticals, Inc. | United States | COM | 28,595 | 38,800 | +10,205 | $12,910,000 | $19,793,000 | +$6,883,000 | 2015-08-12 |
| Q2 2015 | CYH Community Health Systems, Inc. | United States | COM | 70,000 | 148,250 | +78,250 | $3,660,000 | $9,335,000 | +$5,675,000 | 2015-08-12 |
| Q2 2015 | COR AmerisourceBergen Corporation | United States | COM | 10,000 | 60,000 | +50,000 | $1,137,000 | $6,380,000 | +$5,243,000 | 2015-08-12 |
| Q2 2015 | PRGO Perrigo Company plc | Ireland | SHS | 15,000 | 40,000 | +25,000 | $2,333,000 | $7,393,000 | +$5,060,000 | 2015-08-12 |
| Q2 2015 | CHRS Coherus BioSciences, Inc | United States | COM | 80,000 | 250,000 | +170,000 | $2,446,000 | $7,225,000 | +$4,779,000 | 2015-08-12 |
| Q2 2015 | THC Tenet Healthcare Corporation | United States | COM NEW | 50,000 | 121,950 | +71,950 | $2,476,000 | $7,058,000 | +$4,582,000 | 2015-08-12 |
| Q2 2015 | GILD Gilead Sciences, Inc. | United States | COM | 233,810 | 234,900 | +1,090 | $22,944,000 | $27,502,000 | +$4,558,000 | 2015-08-12 |
| Q2 2015 | BDX Becton, Dickinson and Company | United States | COM | 58,608 | 90,630 | +32,022 | $8,416,000 | $12,838,000 | +$4,422,000 | 2015-08-12 |
| Q2 2015 | EW Edwards Lifesciences Corporation | United States | COM | 14,500 | 34,100 | +19,600 | $2,066,000 | $4,857,000 | +$2,791,000 | 2015-08-12 |
| Q2 2015 | MGNX Macrogenics, Inc. | United States | COM | 15,000 | 81,000 | +66,000 | $471,000 | $3,076,000 | +$2,605,000 | 2015-08-12 |
| Q2 2015 | CAH Cardinal Health, Inc. | United States | COM | 90,000 | 123,000 | +33,000 | $8,124,000 | $10,289,000 | +$2,165,000 | 2015-08-12 |
| Q2 2015 | CVS CVS Health Corporation | United States | COM | 30,000 | 50,000 | +20,000 | $3,096,000 | $5,244,000 | +$2,148,000 | 2015-08-12 |
| Q2 2015 | ALKS Alkermes Public Limited Company | SHS | 86,500 | 109,500 | +23,000 | $5,274,000 | $7,045,000 | +$1,771,000 | 2015-08-12 | |
| Q2 2015 | MRK Merck & Co., Inc. | United States | COM | 40,000 | 70,000 | +30,000 | $2,299,000 | $3,985,000 | +$1,686,000 | 2015-08-12 |
| Q2 2015 | NBIX Neurocrine Biosciences, Inc. | United States | COM | 40,000 | 65,000 | +25,000 | $1,588,000 | $3,104,000 | +$1,516,000 | 2015-08-12 |
| Q2 2015 | MASI Masimo Corporation | United States | COM | 50,000 | 75,000 | +25,000 | $1,649,000 | $2,906,000 | +$1,257,000 | 2015-08-12 |
| Q2 2015 | JNJ Johnson & Johnson | United States | COM | 40,000 | 50,000 | +10,000 | $4,024,000 | $4,873,000 | +$849,000 | 2015-08-12 |
| Q2 2015 | BIIB Biogen Inc. | United States | COM | 70,730 | 72,760 | +2,030 | $29,865,000 | $29,391,000 | -$474,000 | 2015-08-12 |
| Q2 2015 | MYGN Myriad Genetics, Inc. | United States | COM | 24,000 | 38,000 | +14,000 | $850,000 | $1,292,000 | +$442,000 | 2015-08-12 |
Similar Firms
| Firm Name | Country | 13F Value | Holdings |
|---|---|---|---|
| Not available yet | |||